Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Active, not recruiting · NCT02756962 · Registry updated 2025-10-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2025-10-28 | NCT02756962 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| American Society of Hematology | 7 |
| The Leukemia and Lymphoma Society | 22 |
| Washington University School of Medicine | 475 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Florida | Gainesville | United States | 70 |
| University of Rochester | Rochester | United States | 360 |
| Washington University School of Medicine | St Louis | United States | 895 |